- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03639428
Pharmacokinetic Evaluation of MDZ028 (MIDAZOLAM)
Pharmacokinetic Evaluation of MDZ028 After Single Administration of a New Oral Form, at the Time of Anesthetic Premedication in Children.
Study Overview
Detailed Description
In the absence of a licensed formulation in many countries worldwide, ADV6209, an innovative 2mg/ml oral solution of midazolam containing cyclodextrin, has been developed for moderate sedation in paediatric patients. Population pharmacokinetics for ADV6209 is reported.
Plasma concentration data were collected from 37 paedriatic patients and 12 healthy adults recruited in a single dose, open-label phase II pharmacokinetic study and in a single dose, randomised, open-label two-peiod crossover bioavailability study, respectively. Data were analysed using non-linear mixed effect modeling. Plasma concentrations of midazolam were discribed by a two-compartement model. An additional one-compartement model was added for a α-hydroxymidazolam.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The planned enrollment is 36 children, stratified in two groups: 24 children between 6 months and 11 years, and 12 children between 12 and 17 years. Age is considered in years past by the date of inclusion. Children aged between 6 months and 11 years old should be homogenous in both age groups 6-23 months and 2-11 years. For example, at least 4 children in the 6-23 month age group will be recruited.
Children likely to be included will be hospitalized in the pediatric surgery department at Amiens University Hospital.
Children who will be included in this study will not be able to participate in another study within 3 months of their inclusion in this study.
Description
Inclusion Criteria:
- Child (boy or girl) for whom surgery under general anesthesia is scheduled.
- Child aged 6 months to 17 years old.
- Child with a body mass index between the 3rd and 97th percentile.
- Child with ASA (American Society of Anesthesiology) status of I or II. Young girl of childbearing age (ie after puberty) and sexually active to have a result negative to the pregnancy test.
- Child whose parents / legal representative (s) agree to sign a consent form.
- Child whose opinion / agreement was / tried to be collected.
- Child and parents / legal representative (s) being ready and able to participate in the study, understanding and undertaking to respect the study procedures throughout the duration of the study.
- Child enrolled in a social security scheme.
Exclusion Criteria:
- Child with midazolam allergy, benzodiazepine hypersensitivity or hypersensitivity known to one of the excipients of the formulation of the study.
- Child with respiratory disease (severe respiratory failure, acute respiratory depression).
- Child with heart disease.
- Child with gastrointestinal disorders that may affect absorption or gastroesophageal reflux.
- Child with growth disorders or abnormal weight-of-weight.
- Child taking Cytochrome P450 Interactions Within 60 Days of Inclusion in the study.
- Child with kidney failure, liver failure, history of myasthenia gravis, or neurological disease.
- Pregnant or lactating girl.
- Child who has a known human immunodeficiency virus (HIV) infection, or active hepatitis B, or active hepatitis C.
- A child who could present any condition that may prevent his participation in the study, according to the judgment of the investigator.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
6 - 23 months
8 infants between 6 and 23 months received a single 0.3mg/kg midazolam dose of ADV6209
|
All subjects received a sigle 0.3mg/kg midazolam dose os ADV6209
Other Names:
|
2-11 years
17 children between 2 and 11 years received a single 0.3mg/kg midazolam dose of ADV6209
|
All subjects received a sigle 0.3mg/kg midazolam dose os ADV6209
Other Names:
|
12-17 years
12 adolescents between 12 and 17 years received a single 0.3mg/kg midazolam dose of ADV6209
|
All subjects received a sigle 0.3mg/kg midazolam dose os ADV6209
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic analysis of the oral solution of midazolam (ADV6209)
Time Frame: 1 day
|
The Aim of the study was to assess the pharmacokinetic analysis of an oral solution of midazolam (ADV6209) oral formulation in paedriatic patients from 6 months to 18 years ols in order to support dosing recommendations.
All subjects received a single 0.3mg/kg midazolam dose of ADV6209, without exceeding a total dose of 10 mg.Population pharmacokinetic modelling was performed to characterise the concentration-time course of midazolam and its main active metabolite, and to evaluate the changes in clearance and volume of distibution in the different age groups.
|
1 day
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Midazolam
Other Study ID Numbers
- PI10-PR-DUPONT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Midazolam
-
Yeungnam University HospitalNot yet recruitingRemimazolam | MidazolamKorea, Republic of
-
Peking UniversityCompletedSedation Complication | Remimazolam | MidazolamChina
-
Guangdong Raynovent Biotech Co., LtdCompletedWarfarin | Drug Drug Interaction | MidazolamChina
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNot yet recruitingPreoperative | Midazolam | DoseChina
-
Peking University People's HospitalEmergency General Hospital; Fenyang Hospital Affiliated to Shanxi Medical UniversityCompletedGastrointestinal Endoscopy | Elderly Patients | Remimazolam | MidazolamChina
-
Astellas Pharma IncCompletedHealthy | Pharmacokinetics of ASP015K and MidazolamUnited States
-
Tanta UniversityCompletedMRI | Dexmedetomidine | Pediatrics | MidazolamEgypt
-
Cukurova UniversityRecruitingSevoflurane | MidazolamTurkey
-
Brugmann University HospitalRecruitingMRI | Dexmedetomidine | Midazolam | Pediatric SedationBelgium
-
Tanta UniversityCompletedAnalgesia | Children, Only | Bupivacaine | MidazolamSaudi Arabia
Clinical Trials on Midazolam
-
PfizerCompleted
-
Seattle Children's HospitalCompleted
-
Jiangsu HengRui Medicine Co., Ltd.CompletedGout and HyperuricemiaChina
-
Nourhan M.AlyAlexandria UniversityCompleted
-
Korea University Anam HospitalCompletedChild | Anesthesia Morbidity | Delirium on EmergenceKorea, Republic of
-
Hamad Medical CorporationCompleted
-
Second Affiliated Hospital of Wenzhou Medical UniversityRecruiting
-
University Hospital, Basel, SwitzerlandCompletedCytochrome P450 CYP3A Enzyme DeficiencySwitzerland
-
Ain Shams UniversityCompleted
-
Nourhan M.AlyCompleted